News
ReNerve’s NervAlign® Nerve Cuff Receives FDA Market Clearance
ReNerve Ltd (ReNerve) today announced that it has received market clearance from the FDA for its NervAlign® Nerve Cuff medical device. This means that the company can now market and sell the product in the United States. The NervAlign® Nerve Cuff is a Class II medical...
ReNerve appoints Emerging Surgical to enter US market
ReNerve Ltd (ReNerve) today announced that it has entered into an agreement with Emerging Surgical in San Diego for the launch, promotion and sales of its NervAlign® Nerve Cuff. ReNerve has filed with the FDA for marketing clearance for its NervAlign® Nerve Cuff and...
ReNerve collaborates with VivaZome to target spinal cord nerve repair
ReNerve has partnered with VivaZome Therapeutics to develop therapeutic solutions for spinal cord repair. The collaboration aims to combine ReNerve’s NervAlign® Nerve Cuff, which is expected to receive marketing approval from the FDA by early 2022, with VivaZome’s...
ReNerve’s NervAlign Nerve Cuff is one step closer to approval
ReNerve’s first product, the NervAlign® Nerve Cuff has reached a major milestone in its pathway to market, with its marketing approval application progressing to the substantial review stage at the FDA. The application was initially submitted in August 2020 and is...
NervAlign products wow surgeons at their annual scientific congress
ReNerve showcased its novel tissue-based products at the Royal Australasian College of Surgeons’ Annual Scientific Congress, held in Melbourne in May. The conference, which had both face-to-face and virtual attendees, is the largest multi-disciplinary meeting held in...